Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
VMF
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine
2. Tak 438
3. Tak-438
4. Tak438
5. Vonoprazan
1. Tak-438
2. 1260141-27-2
3. 881681-01-2
4. Vonoprazan Fumurate
5. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Fumarate
6. Tak 438
7. Tak-438 Monofumarate
8. Vonoprazan Monofumarate
9. Vonoprazan Fumarate (tak-438)
10. 4qw3x4amlb
11. Tak438
12. Unii-4qw3x4amlb
13. Takecab
14. Vocinti
15. (e)-but-2-enedioic Acid;1-[5-(2-fluorophenyl)-1-pyridin-3-ylsulfonylpyrrol-3-yl]-n-methylmethanamine
16. 1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-, (2e)-2-butenedioate (1:1)
17. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Xfumarate
18. 1h-pyrrole-3-methanamine, 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-, 2-butenedioate (1:1)
19. Mfcd18633280
20. Vonoprazan Monofumurate
21. 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl]-n-methylmethanamine Fumarate
22. Takecab (tn)
23. Vonoprazan Fumarate [usan]
24. Schembl194394
25. Schembl194396
26. Chembl2064032
27. Vonoprazan Fumarate [mi]
28. Vonoprazan Fumarate (jan/usan)
29. Ex-a097
30. Vonoprazan Fumarate [jan]
31. Bcp05635
32. Bcp13238
33. Ex-a4001
34. S8016
35. Vonoprazan Fumarate [who-dd]
36. Akos027251052
37. Ccg-269350
38. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Monofumarate
39. 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine (2e)-2-butenedioate
40. Ac-29287
41. Ac-29309
42. Ds-12234
43. Ls-14849
44. Cs-0164592
45. Sw220126-1
46. D10466
47. A854789
48. A900258
49. J-524312
50. Q25104163
51. Tak438 Fumarate;tak-438 Fumarate;tak 438 Fumarate;1260141-27-2
52. 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1h-pyrrol-3-yl)-n-methylmethanamine Fumarate? (vonoprazan Impurity Pound(c)
53. 2098974-13-9
54. 5-(2-fluorophenyl)-n-methyl-1-(3-pyridinylsulfonyl)-1h-pyrrole-3-methanamine 2-butenedioate
| Molecular Weight | 461.5 g/mol |
|---|---|
| Molecular Formula | C21H20FN3O6S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 7 |
| Exact Mass | 461.10568470 g/mol |
| Monoisotopic Mass | 461.10568470 g/mol |
| Topological Polar Surface Area | 147 Ų |
| Heavy Atom Count | 32 |
| Formal Charge | 0 |
| Complexity | 629 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 1 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]EU WC
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Listed Suppliers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]INTERMEDIATE SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
DATA COMPILATION #PharmaFlow
NEWS #PharmaBuzz
Global Sales Information
US Medicaid Prescriptions
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
36
PharmaCompass offers a list of Vonoprazan Fumarate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Vonoprazan Fumarate manufacturer or Vonoprazan Fumarate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Vonoprazan Fumarate manufacturer or Vonoprazan Fumarate supplier.
PharmaCompass also assists you with knowing the Vonoprazan Fumarate API Price utilized in the formulation of products. Vonoprazan Fumarate API Price is not always fixed or binding as the Vonoprazan Fumarate Price is obtained through a variety of data sources. The Vonoprazan Fumarate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A 1260141-27-2 (fumarate) manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of 1260141-27-2 (fumarate), including repackagers and relabelers. The FDA regulates 1260141-27-2 (fumarate) manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. 1260141-27-2 (fumarate) API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of 1260141-27-2 (fumarate) manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A 1260141-27-2 (fumarate) supplier is an individual or a company that provides 1260141-27-2 (fumarate) active pharmaceutical ingredient (API) or 1260141-27-2 (fumarate) finished formulations upon request. The 1260141-27-2 (fumarate) suppliers may include 1260141-27-2 (fumarate) API manufacturers, exporters, distributors and traders.
click here to find a list of 1260141-27-2 (fumarate) suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A 1260141-27-2 (fumarate) DMF (Drug Master File) is a document detailing the whole manufacturing process of 1260141-27-2 (fumarate) active pharmaceutical ingredient (API) in detail. Different forms of 1260141-27-2 (fumarate) DMFs exist exist since differing nations have different regulations, such as 1260141-27-2 (fumarate) USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A 1260141-27-2 (fumarate) DMF submitted to regulatory agencies in the US is known as a USDMF. 1260141-27-2 (fumarate) USDMF includes data on 1260141-27-2 (fumarate)'s chemical properties, information on the facilities and procedures used, and details about packaging and storage. The 1260141-27-2 (fumarate) USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of 1260141-27-2 (fumarate) suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a 1260141-27-2 (fumarate) Drug Master File in Korea (1260141-27-2 (fumarate) KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of 1260141-27-2 (fumarate). The MFDS reviews the 1260141-27-2 (fumarate) KDMF as part of the drug registration process and uses the information provided in the 1260141-27-2 (fumarate) KDMF to evaluate the safety and efficacy of the drug.
After submitting a 1260141-27-2 (fumarate) KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their 1260141-27-2 (fumarate) API can apply through the Korea Drug Master File (KDMF).
click here to find a list of 1260141-27-2 (fumarate) suppliers with KDMF on PharmaCompass.
A 1260141-27-2 (fumarate) written confirmation (1260141-27-2 (fumarate) WC) is an official document issued by a regulatory agency to a 1260141-27-2 (fumarate) manufacturer, verifying that the manufacturing facility of a 1260141-27-2 (fumarate) active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting 1260141-27-2 (fumarate) APIs or 1260141-27-2 (fumarate) finished pharmaceutical products to another nation, regulatory agencies frequently require a 1260141-27-2 (fumarate) WC (written confirmation) as part of the regulatory process.
click here to find a list of 1260141-27-2 (fumarate) suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing 1260141-27-2 (fumarate) as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for 1260141-27-2 (fumarate) API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture 1260141-27-2 (fumarate) as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain 1260141-27-2 (fumarate) and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a 1260141-27-2 (fumarate) NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of 1260141-27-2 (fumarate) suppliers with NDC on PharmaCompass.
1260141-27-2 (fumarate) Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of 1260141-27-2 (fumarate) GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right 1260141-27-2 (fumarate) GMP manufacturer or 1260141-27-2 (fumarate) GMP API supplier for your needs.
A 1260141-27-2 (fumarate) CoA (Certificate of Analysis) is a formal document that attests to 1260141-27-2 (fumarate)'s compliance with 1260141-27-2 (fumarate) specifications and serves as a tool for batch-level quality control.
1260141-27-2 (fumarate) CoA mostly includes findings from lab analyses of a specific batch. For each 1260141-27-2 (fumarate) CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
1260141-27-2 (fumarate) may be tested according to a variety of international standards, such as European Pharmacopoeia (1260141-27-2 (fumarate) EP), 1260141-27-2 (fumarate) JP (Japanese Pharmacopeia) and the US Pharmacopoeia (1260141-27-2 (fumarate) USP).
